GHDX News and Press, Genomic Health Inc. From 09/10/19

NEW YORK, NY / ACCESSWIRE / September 10, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Genomic Health, Inc. (NASDAQ: ...

- Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy - Oncotype DX® test recommended based on prospective landmark TAILORx and German Pla...

NEW YORK, NY / ACCESSWIRE / August 16, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Rudolp...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

NEW YORK , Aug. 9, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating: Genomic Health, Inc. ( GHDX ) ("Genomic"...

Merger activity decreased last week with three new deals announced and ten pending deals closing. Deal Statistics: New Deals: The acquisition of Genomic Health ([[GHDX]]) by Exact Sciences Corporation ([[EXAS]]) for $2.8 billion in a cash-plus-stock deal. Under the terms of the ...

Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Genomic Health, Inc. (NASDAQ: GHDX) by Exact Sciences Corp. (NASDAQ: EXAS). On July 29, 2019, the two companies announced the signing of a definitive merger agreement pursuant to which Exact Sci...

Read more ...

NEW YORK, NY / ACCESSWIRE / August 1, 2019 / Halper Sadeh LLP, a global investor rights law firm, reminds investors that it is investigating the following companies: LegacyTexas Financial Group, Inc. (NASDAQ: LTXB) The investigation concerns whether LegacyTexas and i...

Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up  8%  premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...